Developer docs
API playgroundTry for free, no card

Search company profiles

ChemDiv

Full company profile

uuid000a5pw

Namestring
ChemDiv
Legal namestring
ChemDiv Inc.
Websiteurl
chemdiv.com
Company typeenum
Private
Founded yearint
1994
Descriptiontext

ChemDiv Inc. is a privately held, San Diego-headquartered drug discovery solutions provider founded in 1994, serving pharmaceutical, biotechnology, academic, and screening-center customers in the US, Europe, and Asia. The company operates a 501-1,000 person organization with regional representative offices in South Korea, Japan, and China, offering both a transactional compound catalog and a full-service integrated discovery platform.

The company's core offering combines a physical and virtual chemical inventory—1.6 million stock-available screening compounds, 12 million units of managed global inventory, 75,000+ building blocks, 45,000+ inhibitors, 114 predesigned focused libraries, and 2 trillion synthetically feasible structures—with a hybrid AI/ML drug discovery platform curated by scientists. Proprietary tools include GPU-accelerated 3D docking (CombiRIDGE), in-situ conformer generation (GINGER), the Rapid Isostere Discovery Engine (RIDE), AI Kinome Profiling, in silico CADD services, and validated AI/ML training datasets. The integrated services workflow spans Target ID, Lead Discovery, Lead Optimization, IND-enabling studies, FIM studies, and Clinical Proof of Concept, supported by medicinal chemistry, discovery biology, ADME/DMPK, in vivo models, safety/toxicology, and CMC capabilities.

ChemDiv generates revenue through three streams: (1) one-time per-compound sales of screening compounds and libraries via its chemdiv.com e-commerce storefront and direct outreach; (2) professional-services contracts for integrated end-to-end drug discovery engagements with named partners such as Mondego Bio, Polku Therapeutics, Brenig Therapeutics, Traws Pharma, and Barinthus Biotherapeutics; and (3) CMC services. Pricing is quote-based and not publicly disclosed, with deep partnerships spanning CNS, oncology, infectious disease, and cardiometabolic indications across 200+ validated partner laboratories.

Short descriptiontext

ChemDiv is a privately held, San Diego-headquartered drug discovery solutions provider offering 1.6 million screening compounds, a 1B virtual chemical space, proprietary AI/ML discovery tools, and integrated Target ID through Clinical POC services to pharmaceutical, biotech, academic, and screening-center customers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, screening compound libraries, medicinal chemistry, building blocks catalog, computational drug design
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Chemicals & Allied Products2800
Product category
Drug Discovery Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Screening Compound and Library Sales
TypeOne Time License
Description

Sale of 1.6 million stock available screening compounds, focused/targeted libraries, diversity libraries, preplated libraries, building blocks (75K+), inhibitors and approved drugs (45K+), and natural compounds. Customers can purchase online through the e-commerce platform with compounds available in various formats (dry powders, DMSO solutions, 96/384-well plates).

chemdiv.com
2Integrated Drug Discovery Services
TypeProfessional Services
Description

Full-service drug discovery including target ID, lead discovery, lead optimization, synthetic and medicinal chemistry, discovery biology, ADME/DMPK, in vivo/ex vivo models, safety and toxicology, and clinical proof of concept studies. Services support partners like Polku Therapeutics, Brenig Therapeutics, and Mondego Bio.

chemdiv.com
3CMC Services
TypeProfessional Services
Description

Chemistry, Manufacturing and Controls services including manufacturing, medicinal chemistry, and predictive pharmacology services for clinical and regulatory progress. Extended collaboration with Traws Pharma for ratutrelvir COVID-19 therapeutic.

sdbn.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based pricing for screening compound libraries
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing varies based on compound selection, quantity, format (dry powder vs DMSO solution), plate format (96/384-well), and delivery requirements. No public pricing listed; requires direct inquiry.

chemdiv.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ChemDiv fundamentally provides integrated drug discovery solutions comprising a catalog of 1.6 million stock-available screening compounds, 100+ focused and targeted libraries, a 75,000+ building blocks collection, and a 1 billion virtual chemical space, sold alongside end-to-end discovery services spanning target identification, lead discovery, lead optimization, ADME/DMPK, in vivo models, safety/toxicology, CMC manufacturing, and clinical proof of concept, all supported by a proprietary AI/ML platform and GPU-accelerated computational tools.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successfully completed hundreds of leads, candidates and new drug programs over 32 years
+2 more records
Product overview1 text field

ChemDiv is a global provider of integrated drug discovery solutions offering a comprehensive portfolio of screening compounds, chemical libraries, and discovery services. The core offering consists of the Screening Compounds Catalog (1.6M compounds) and Screening Libraries (100+ focused/targeted libraries organized by therapeutic areas and target families), supported by a Building Blocks Collection (75K compounds) and Virtual Chemical Space (1B virtual compounds). The service platform encompasses Integrated Drug Discovery Services spanning Target ID through Clinical POC, AI-driven capabilities (AI Kinome Profile, AI/ML Datasets), CMC Services, and specialized technology features (CombiRIDGE, In-situ GINGER, RIDE) for virtual screening and compound generation. The company has over 32 years of experience completing hundreds of leads, candidates, and new drug programs for pharma, biotech, and academic partners globally.

Product and service8 records
1Screening Compounds Catalog
CategoryScreening Compounds
Description

Online catalog of 1.6 million stock-available screening compounds offered for purchase in multiple formats (dry powders, DMSO solutions, 96/384-well plates) by pharmaceutical, biotech, and academic buyers for hit identification and screening campaigns.

2Screening Libraries
CategoryCompound Libraries
Description

Over 100 pre-designed focused and targeted compound libraries, plus 17 annotated libraries with bioactivity data, covering therapeutic areas, target families, and mechanisms of action for pharma, biotech, and academic screening programs.

3Building Blocks Collection
CategoryBuilding Blocks
Description

75,000 stock-available building blocks for medicinal chemistry projects, combinatorial library generation, and hit-to-lead optimization, with NMR and LC-MS quality control and >90% purity guarantee.

4Virtual Chemical Space
CategoryVirtual Compound Library
Description

1 billion virtual compound library validated and built upon commercially available anchors, building blocks, and cores, with 2D fingerprint and substructure search and GPU-accelerated virtual screening for hit identification and lead generation.

5AI Kinome Profile
CategoryIn Silico CADD Services
Description

AI-driven kinome-wide selectivity profiling service for drug discovery teams, providing comprehensive kinase target assessment using ChemDiv's proprietary datasets to support target identification and selectivity optimization.

6AI/ML Datasets
CategoryAI/ML Data
Description

Validated proprietary AI/ML training datasets with verified experimental data, balanced activity representation, standardized conditions, and comprehensive ADMET profiles, offered for ML-ready model training in drug discovery.

7Integrated Drug Discovery Services
CategoryDrug Discovery Services
Description

Full-spectrum drug discovery services covering target identification, lead discovery, lead optimization, IND-enabling studies, FIM studies, and clinical proof of concept, including medicinal chemistry, in silico CADD, discovery biology, ADME/DMPK, in vivo models, and safety/toxicology, for pharma and biotech partners.

8CMC Services
CategoryCMC Services
Description

Chemistry, Manufacturing and Controls (CMC) services including scale-up manufacturing, medicinal chemistry, predictive pharmacology, and regulatory progression support for clinical-stage development programs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Long-term collaboration leveraging ChemDiv's proprietary CNS-focused drug discovery platform for neurodegenerative disease programs. Polku Therapeutics reported positive efficacy results for lead compound POLK-38, demonstrating significant treatment effects on brain tau pathology and spatial learning in a PS19 tauopathy mouse model.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Collaboration using ChemDiv's CNS drug discovery platform for programs targeting LRRK2 and NLRP3 pathways, which have advanced into clinical development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

Extended CMC services collaboration supporting clinical development of ratutrelvir, an oral COVID-19 therapeutic in Phase 2 trials. Services include manufacturing, medicinal chemistry, and predictive pharmacology to support clinical and regulatory progress.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

Extended partnership for best-in-class PTPN2 immuno-oncology program. Collaboration involves drug discovery, scale-up manufacturing, and accelerating clinical readiness, supported by facilities across Europe and the U.S.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

ChemDiv continues providing R&D services support following Clywedog Therapeutics' merger with Barinthus Biotherapeutics. Barinthus is developing VTP-300 for hepatitis B and VTP-1000 for celiac disease using viral vector and synthetic platform technologies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Evotec is a global integrated drug discovery CRO offering target identification through clinical candidate services to pharma and biotech partners, with a similar end-to-end services model and AI-enabled platforms (e.g., EVOpanHunter). Direct overlap with ChemDiv in offering Target ID through IND-enabling workflows and library/design services.

TypeDirect peer
Description

MedChemExpress is a major supplier of screening compounds, inhibitors, building blocks, and natural products to pharma, biotech, and academic researchers globally, with transparent online catalog pricing. Direct overlap with ChemDiv's catalog sales and self-service e-commerce model, though MCE is more catalog-focused and less service-heavy.

TypeDirect peer
Description

Enamine is a leading supplier of screening compounds, building blocks, and pre-plated libraries, and offers REAL Database virtual chemical space and custom synthesis. Direct overlap with ChemDiv's compound catalog, building blocks (75K+), and 1B virtual space offering, with comparable catalog-driven business model.

TypeDirect peer
Description

Reaction Biology provides early-stage drug discovery services including compound screening, medicinal chemistry, and biology/protein production services to biotech and pharma. Comparable integrated discovery CRO model at smaller scale, with similar target customer profile.

TypeBroad incumbent
Description

Eurofins Discovery offers integrated drug discovery services including compound libraries (e.g., Eurofins Discovery Services, PanLabs), in vitro pharmacology, ADME, and in vivo studies for pharma/biotech. Comparable integrated discovery footprint with established global scale.

TypeBroad incumbent
Description

WuXi AppTec operates a global discovery CRO platform (WuXi Biology, WuXi Chemistry) providing compound libraries, medicinal chemistry, DMPK, in vivo pharmacology, and CMC services to pharma and biotech. Comparable integrated discovery footprint, though at much larger scale and with broader capabilities including biologics.

TypeDirect peer
Description

Tocris (a Bio-Techne brand) supplies high-purity small molecules, inhibitors, and tool compounds to neuroscience and other therapeutic-area researchers. Comparable in catalog chemical supply with quality focus, though more product-focused and less service-oriented than ChemDiv.

TypeBroad incumbent
Description

Charles River is a large, established CRO with a Discovery & Safety Assessment segment offering compound libraries, medicinal chemistry, in vitro/in vivo biology, and integrated discovery services to pharma/biotech. Overlaps with ChemDiv on library sales and integrated discovery, but operates at much larger scale with broader service portfolio.

TypeEmerging player
Description

MolPort operates a chemical sourcing marketplace aggregating compound inventories from multiple suppliers with online search and purchasing. Adjacent competitor in the compound procurement workflow; less focused on proprietary libraries and integrated services than ChemDiv but overlaps on catalog access for screening compounds.

TypeDirect peer
Description

Life Chemicals supplies screening compound libraries, building blocks, and custom synthesis services, with focus on focused/targeted libraries similar to ChemDiv's 114 predesigned libraries. Direct peer in the catalog and library supply segment with similar customer base in pharma/biotech screening.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ChemDiv

Drug Discovery Serviceschemdiv.com

ChemDiv is a privately held, San Diego-headquartered drug discovery solutions provider offering 1.6 million screening compounds, a 1B virtual chemical space, proprietary AI/ML discovery tools, and integrated Target ID through Clinical POC services to pharmaceutical, biotech, academic, and screening-center customers globally.

What ChemDiv does

ChemDiv Inc. is a privately held, San Diego-headquartered drug discovery solutions provider founded in 1994, serving pharmaceutical, biotechnology, academic, and screening-center customers in the US, Europe, and Asia. The company operates a 501-1,000 person organization with regional representative offices in South Korea, Japan, and China, offering both a transactional compound catalog and a full-service integrated discovery platform.

The company's core offering combines a physical and virtual chemical inventory—1.6 million stock-available screening compounds, 12 million units of managed global inventory, 75,000+ building blocks, 45,000+ inhibitors, 114 predesigned focused libraries, and 2 trillion synthetically feasible structures—with a hybrid AI/ML drug discovery platform curated by scientists. Proprietary tools include GPU-accelerated 3D docking (CombiRIDGE), in-situ conformer generation (GINGER), the Rapid Isostere Discovery Engine (RIDE), AI Kinome Profiling, in silico CADD services, and validated AI/ML training datasets. The integrated services workflow spans Target ID, Lead Discovery, Lead Optimization, IND-enabling studies, FIM studies, and Clinical Proof of Concept, supported by medicinal chemistry, discovery biology, ADME/DMPK, in vivo models, safety/toxicology, and CMC capabilities.

ChemDiv generates revenue through three streams: (1) one-time per-compound sales of screening compounds and libraries via its chemdiv.com e-commerce storefront and direct outreach; (2) professional-services contracts for integrated end-to-end drug discovery engagements with named partners such as Mondego Bio, Polku Therapeutics, Brenig Therapeutics, Traws Pharma, and Barinthus Biotherapeutics; and (3) CMC services. Pricing is quote-based and not publicly disclosed, with deep partnerships spanning CNS, oncology, infectious disease, and cardiometabolic indications across 200+ validated partner laboratories.

ChemDiv firmographics

Firmographics
Name
ChemDiv
Legal name
ChemDiv Inc.
Website
https://chemdiv.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
51–100 employees
Short description
ChemDiv is a privately held, San Diego-headquartered drug discovery solutions provider offering 1.6 million screening compounds, a 1B virtual chemical space, proprietary AI/ML discovery tools, and integrated Target ID through Clinical POC services to pharmaceutical, biotech, academic, and screening-center customers globally.
Ownership category
akta.pro rank

ChemDiv industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Medicinal Chemicals & Botanical Products (2833), Chemicals & Allied Products (2800)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Drug discovery services
  • Screening compound libraries
  • Medicinal chemistry
  • Building blocks catalog
  • Computational drug design

Where ChemDiv is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices4 records

Markets served

ChemDiv business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Screening Compound and Library Sales: Sale of 1.6 million stock available screening compounds, focused/targeted libraries, diversity libraries, preplated libraries, building blocks (75K+), inhibitors and approved drugs (45K+), and natural compounds. Customers can purchase online through the e-commerce platform with compounds available in various formats (dry powders, DMSO solutions, 96/384-well plates).
  2. Integrated Drug Discovery Services: Full-service drug discovery including target ID, lead discovery, lead optimization, synthetic and medicinal chemistry, discovery biology, ADME/DMPK, in vivo/ex vivo models, safety and toxicology, and clinical proof of concept studies. Services support partners like Polku Therapeutics, Brenig Therapeutics, and Mondego Bio.
  3. CMC Services: Chemistry, Manufacturing and Controls services including manufacturing, medicinal chemistry, and predictive pharmacology services for clinical and regulatory progress. Extended collaboration with Traws Pharma for ratutrelvir COVID-19 therapeutic.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing for screening compound libraries

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

ChemDiv product offering

Product offering

Core offering

ChemDiv fundamentally provides integrated drug discovery solutions comprising a catalog of 1.6 million stock-available screening compounds, 100+ focused and targeted libraries, a 75,000+ building blocks collection, and a 1 billion virtual chemical space, sold alongside end-to-end discovery services spanning target identification, lead discovery, lead optimization, ADME/DMPK, in vivo models, safety/toxicology, CMC manufacturing, and clinical proof of concept, all supported by a proprietary AI/ML platform and GPU-accelerated computational tools.

Product overview

ChemDiv is a global provider of integrated drug discovery solutions offering a comprehensive portfolio of screening compounds, chemical libraries, and discovery services. The core offering consists of the Screening Compounds Catalog (1.6M compounds) and Screening Libraries (100+ focused/targeted libraries organized by therapeutic areas and target families), supported by a Building Blocks Collection (75K compounds) and Virtual Chemical Space (1B virtual compounds). The service platform encompasses Integrated Drug Discovery Services spanning Target ID through Clinical POC, AI-driven capabilities (AI Kinome Profile, AI/ML Datasets), CMC Services, and specialized technology features (CombiRIDGE, In-situ GINGER, RIDE) for virtual screening and compound generation. The company has over 32 years of experience completing hundreds of leads, candidates, and new drug programs for pharma, biotech, and academic partners globally.

Differentiator

Problem solved

Functional benefit

Products and services

  • Screening Compounds Catalog Online catalog of 1.6 million stock-available screening compounds offered for purchase in multiple formats (dry powders, DMSO solutions, 96/384-well plates) by pharmaceutical, biotech, and academic buyers for hit identification and screening campaigns.
  • Screening Libraries Over 100 pre-designed focused and targeted compound libraries, plus 17 annotated libraries with bioactivity data, covering therapeutic areas, target families, and mechanisms of action for pharma, biotech, and academic screening programs.
  • Building Blocks Collection 75,000 stock-available building blocks for medicinal chemistry projects, combinatorial library generation, and hit-to-lead optimization, with NMR and LC-MS quality control and >90% purity guarantee.
  • Virtual Chemical Space 1 billion virtual compound library validated and built upon commercially available anchors, building blocks, and cores, with 2D fingerprint and substructure search and GPU-accelerated virtual screening for hit identification and lead generation.
  • AI Kinome Profile AI-driven kinome-wide selectivity profiling service for drug discovery teams, providing comprehensive kinase target assessment using ChemDiv's proprietary datasets to support target identification and selectivity optimization.
  • AI/ML Datasets Validated proprietary AI/ML training datasets with verified experimental data, balanced activity representation, standardized conditions, and comprehensive ADMET profiles, offered for ML-ready model training in drug discovery.
  • Integrated Drug Discovery Services Full-spectrum drug discovery services covering target identification, lead discovery, lead optimization, IND-enabling studies, FIM studies, and clinical proof of concept, including medicinal chemistry, in silico CADD, discovery biology, ADME/DMPK, in vivo models, and safety/toxicology, for pharma and biotech partners.
  • CMC Services Chemistry, Manufacturing and Controls (CMC) services including scale-up manufacturing, medicinal chemistry, predictive pharmacology, and regulatory progression support for clinical-stage development programs.

Quantifiable outcome

  • Successfully completed hundreds of leads, candidates and new drug programs over 32 years
  • +2 more outcomes

Companies that use ChemDiv

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

ChemDiv technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature8 records

ChemDiv partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Polku TherapeuticscoreStrategic or Co-development Partner · 22 June 2026Long-term collaboration leveraging ChemDiv's proprietary CNS-focused drug discovery platform for neurodegenerative disease programs. Polku Therapeutics reported positive efficacy results for lead compound POLK-38, demonstrating significant treatment effects on brain tau pathology and spatial learning in a PS19 tauopathy mouse model.
  • Brenig TherapeuticscoreStrategic or Co-development Partner · 22 June 2026Collaboration using ChemDiv's CNS drug discovery platform for programs targeting LRRK2 and NLRP3 pathways, which have advanced into clinical development.
  • Traws PharmacoreStrategic or Co-development Partner · 30 October 2025Extended CMC services collaboration supporting clinical development of ratutrelvir, an oral COVID-19 therapeutic in Phase 2 trials. Services include manufacturing, medicinal chemistry, and predictive pharmacology to support clinical and regulatory progress.
  • Mondego BiocoreStrategic or Co-development Partner · 24 October 2025Extended partnership for best-in-class PTPN2 immuno-oncology program. Collaboration involves drug discovery, scale-up manufacturing, and accelerating clinical readiness, supported by facilities across Europe and the U.S.
  • Clywedog Therapeutics (Barinthus Biotherapeutics)minorStrategic or Co-development Partner · 24 October 2025ChemDiv continues providing R&D services support following Clywedog Therapeutics' merger with Barinthus Biotherapeutics. Barinthus is developing VTP-300 for hepatitis B and VTP-1000 for celiac disease using viral vector and synthetic platform technologies.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

ChemDiv competitors and assessment

Company assessment

Direct peers

  • Evotec SE: Evotec is a global integrated drug discovery CRO offering target identification through clinical candidate services to pharma and biotech partners, with a similar end-to-end services model and AI-enabled platforms (e.g., EVOpanHunter). Direct overlap with ChemDiv in offering Target ID through IND-enabling workflows and library/design services.
  • MedChemExpress (MCE): MedChemExpress is a major supplier of screening compounds, inhibitors, building blocks, and natural products to pharma, biotech, and academic researchers globally, with transparent online catalog pricing. Direct overlap with ChemDiv's catalog sales and self-service e-commerce model, though MCE is more catalog-focused and less service-heavy.
  • Enamine Ltd. Enamine is a leading supplier of screening compounds, building blocks, and pre-plated libraries, and offers REAL Database virtual chemical space and custom synthesis. Direct overlap with ChemDiv's compound catalog, building blocks (75K+), and 1B virtual space offering, with comparable catalog-driven business model.
  • Reaction Biology Corporation: Reaction Biology provides early-stage drug discovery services including compound screening, medicinal chemistry, and biology/protein production services to biotech and pharma. Comparable integrated discovery CRO model at smaller scale, with similar target customer profile.
  • Tocris Bioscience (Bio-Techne): Tocris (a Bio-Techne brand) supplies high-purity small molecules, inhibitors, and tool compounds to neuroscience and other therapeutic-area researchers. Comparable in catalog chemical supply with quality focus, though more product-focused and less service-oriented than ChemDiv.
  • Life Chemicals: Life Chemicals supplies screening compound libraries, building blocks, and custom synthesis services, with focus on focused/targeted libraries similar to ChemDiv's 114 predesigned libraries. Direct peer in the catalog and library supply segment with similar customer base in pharma/biotech screening.

Broad incumbents

  • Eurofins Discovery: Eurofins Discovery offers integrated drug discovery services including compound libraries (e.g., Eurofins Discovery Services, PanLabs), in vitro pharmacology, ADME, and in vivo studies for pharma/biotech. Comparable integrated discovery footprint with established global scale.
  • WuXi AppTec: WuXi AppTec operates a global discovery CRO platform (WuXi Biology, WuXi Chemistry) providing compound libraries, medicinal chemistry, DMPK, in vivo pharmacology, and CMC services to pharma and biotech. Comparable integrated discovery footprint, though at much larger scale and with broader capabilities including biologics.
  • Charles River Laboratories: Charles River is a large, established CRO with a Discovery & Safety Assessment segment offering compound libraries, medicinal chemistry, in vitro/in vivo biology, and integrated discovery services to pharma/biotech. Overlaps with ChemDiv on library sales and integrated discovery, but operates at much larger scale with broader service portfolio.

Emerging players

  • MolPort: MolPort operates a chemical sourcing marketplace aggregating compound inventories from multiple suppliers with online search and purchasing. Adjacent competitor in the compound procurement workflow; less focused on proprietary libraries and integrated services than ChemDiv but overlaps on catalog access for screening compounds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ChemDiv social profiles

Digital presence

ChemDiv financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ChemDiv leadership team

Management profile

Number of profiles

Profiles2 records

ChemDiv funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ChemDiv M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChemDiv

What does ChemDiv do?

ChemDiv fundamentally provides integrated drug discovery solutions comprising a catalog of 1.6 million stock-available screening compounds, 100+ focused and targeted libraries, a 75,000+ building blocks collection, and a 1 billion virtual chemical space, sold alongside end-to-end discovery services spanning target identification, lead discovery, lead optimization, ADME/DMPK, in vivo models, safety/toxicology, CMC manufacturing, and clinical proof of concept, all supported by a proprietary AI/ML platform and GPU-accelerated computational tools.

Is ChemDiv a public or private company?

ChemDiv is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ChemDiv founded?

ChemDiv was founded in 1994. It employs 51 to 100 people.

Where is ChemDiv based?

ChemDiv is headquartered in San Diego, United States, in the North America region.

How does ChemDiv make money?

Three revenue lines are on record. Screening Compound and Library Sales are the primary driver. The others are integrated Drug Discovery Services and CMC Services.

Who are ChemDiv's main competitors?

Direct peers on record are Evotec SE, MedChemExpress (MCE), Enamine Ltd., Reaction Biology Corporation, Tocris Bioscience (Bio-Techne) and Life Chemicals. Broad incumbents are Eurofins Discovery, WuXi AppTec and Charles River Laboratories. MolPort is listed as an emerging player.

Does ChemDiv have an API?

No public API is recorded for ChemDiv.

What industry is ChemDiv in?

ChemDiv's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BiotechniquesThe biotech bi-weekly: partnerships facilitating antibody discovery and AI drug developmentThis bi-weekly roundup covers multiple recent partnerships and platform advances in the biotech sector focused on antibody discovery and AI-driven drug development. Key collaborations include Zymeworks partnering with Gandeeva Therapeutics for cryo-EM visualization of antibody-antigen interfaces, Jazz Pharmaceuticals and AbCellera joining forces on T-cell engaging multispecific antibodies for solid tumors, and Harbour BioMed's long-term AI partnership with BioMap for complex biologics discovery. Additional developments include ChemDiv's CNS-focused drug discovery platform milestones, FairJourney Bio's transgenic mouse antibody discovery partnership with AbTherx, Oxford Nanopore Technologies reaching the MacRobert Award finalist stage, and Takara Bio showcasing its spatial biology technology.PR NewswireChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig TherapeuticsChemDiv, Inc., a global provider of integrated drug discovery solutions, announced significant milestones achieved through its proprietary CNS-focused drug discovery platform, which has enabled the design and optimization of brain-penetrant small-molecule programs for its partners Polku Therapeutics and Brenig Therapeutics. Polku Therapeutics reported positive efficacy results for its lead compound POLK-38, demonstrating significant treatment effects on brain tau pathology and spatial learning in a PS19 tauopathy mouse model, while Brenig Therapeutics advanced programs targeting LRRK2 and NLRP3 pathways into clinical development. These advancements underscore the platform's capability in supporting discovery programs for complex central nervous system exposure and neurodegenerative diseases.BioSpaceChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig TherapeuticsChemDiv announced its CNS drug discovery platform enabled brain-penetrant programs for Polku and Brenig. Polku's POLK-38 showed positive efficacy in the PS19 tauopathy mouse model, and Brenig's LRRK2/NLRP3 programs advanced to clinical development. Polku will present new data at AAIC on July 12, 2026.BioSpaceChemDiv’s Discovery Platform Enables Differentiated, Reversible Pan‑EGFR Kinase Inhibitors for GFR‑Mutant Lung CancerChemDiv announced platform enhancements for developing reversible pan-EGFR kinase inhibitors targeting EGFR-mutant non-small cell lung cancer, integrating AI-guided design, kinome-wide selectivity modeling, and parallel synthesis to achieve broad mutant coverage while sparing wild-type EGFR. A partner collaboration has progressed from late lead-optimization into process route scouting, multi-gram scale-up, and early CMC activities including solid-form assessment and pre-formulation. The advancements aim to support pre-IND readiness while maintaining optionality for combination studies.Stock TitanChemDiv Extends CMC Support for Ratutrelvir as Phase 2 AdvancesChemDiv extended its CMC services collaboration for ratutrelvir, an oral COVID-19 antiviral, as Traws Pharma dosed the first patient in Phase 2 studies in October 2025. Top-line data from the non-inferiority trial against PAXLOVID is expected by year-end 2025. The drug is also in a single-arm trial for PAXLOVID-ineligible patients.INNChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical TrialsChemDiv has extended its CMC services collaboration for Ratutrelvir, a COVID-19 therapeutic candidate currently in Phase 2 clinical trials. Ratutrelvir is considered a potential best-in-class treatment.PR NewswireChemDiv's Discovery Platform Enables Differentiated, Reversible Pan‑EGFR Kinase Inhibitors for GFR‑Mutant Lung CancerChemDiv, a global drug discovery provider based in San Diego, announced enhanced capabilities in its discovery platform for developing reversible pan-EGFR kinase inhibitors targeting EGFR-mutant non-small cell lung cancer. The upgraded platform integrates AI-guided chem-bio design, kinome-wide selectivity modeling, and parallel synthesis to achieve broad mutant coverage while minimizing wild-type EGFR inhibition, aiming to improve the therapeutic window and safety profile. A partner collaboration has advanced from late lead-optimization into process route scouting and multi-gram scale-up, with early CMC activities including solid-form assessment and pre-formulation now underway toward pre-IND readiness.SdbnChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials – San Diego Biotechnology NetworkChemDiv announced an extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical development of ratutrelvir, an oral COVID-19 therapeutic currently advancing in Phase 2 clinical trials. Ratutrelvir is being developed as a potential best-in-class COVID-19 treatment. This extension continues ChemDiv's provision of integrated drug discovery solutions for the program.